White Paper

Booth L05 for Clinically Backed NMN & Liposomal VC

Overview

This year’s Vitafoods Asia, EffePharm will showcase innovative anti-aging solutions, featuring Uthever® NMN, the world’s first large-scale, human clinically-proven NMN brand.

Also discover clinically-backed ingredient delivery technologies for enhanced bioavailability and functionality, featuring LipoAvail® liposomal VC and more. LipoAvail® vitamin C offers enhanced health benefits such as better absorption, immune support, skin radiance, and antioxidant protection—all backed by scientific data.

Download the NMN Whitepaper to learn more.

This content is paid by Effepharm Ltd, and any views and opinions expressed do not necessarily reflect those of NutraIngredients.com

Download Now

Latest Content

NMN supplementation proved to mitigate radiotherapy-induced damages

Paid for by Effepharm Ltd

Scientific study validates NMN’s efficacy in alleviating intestinal damages caused by radiotherapy through reducing alterations to gut bacteria composition and function.

NMN New Clinical Finding: Obvious NAD(H) Level Increase

Paid for by Effepharm Ltd

With 7.3% CAGR, The "Nicotinamide Mononucleotide (NMN) Market" size is expected to grow from 194.2 million USD In 2020, to reach 296.5 Million USD by 2026.”